TICKERNERD
Menu
XFORXFORHealthcare · Biotechnology

XFOR Stock Forecast: X4 Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.50
+2.94% on the day

The 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +242.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$347.0M
Ticker Nerd rank
62 / 100
Median analyst target
$12
Analysts covering
5
Revenue$8.8M+346.3% y/y
Operating income−$16.4M
Net income−$16.2M
Free cash flow−$25.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.4%
1M
−18.2%
YTD
−12.5%
1Y
+6.1%
From 52W high
−25.1%
From 52W low
+22.4%
$2.86
$4.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XFOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores X4 Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Momentum
82
Growth
77
Size
59
Quality
49
Accruals
36
Value
32
Issuance
29
Volatility
23

Revisions (89): Analysts have, on balance, been raising their forecasts.

Volatility (23): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XFOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XFOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26XFORHigh $13Median $12Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $10Median $12High $13

The green dot is the last close — the median target sits +242.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 July 2026Wells FargoInitiatesOverweight$11
2 June 2026Leerink PartnersInitiatesOutperform—
9 Mar 2026GuggenheimInitiatesBuy—
5 Dec 2025StifelMaintainsBuy—
10 Nov 2025HC Wainwright & Co.MaintainsBuy—
29 Aug 2025StifelMaintainsBuy—
13 Aug 2025HC Wainwright & Co.MaintainsBuy—
2 May 2025HC Wainwright & Co.MaintainsBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.MaintainsBuy—
14 Nov 2024StifelMaintainsBuy—
28 June 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024Cantor FitzgeraldReiteratesOverweight—
30 Apr 2024HC Wainwright & Co.MaintainsBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2023B. Riley SecuritiesDowngradeNeutral—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XFOR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XFOR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, X4 Pharmaceuticals, Inc. returned +6.1% against +17.5% for the S&P 500, dividends included.

XFOR vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26XFORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XFOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

X4 Pharmaceuticals, Inc. (XFOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
21.9×

Cheaper than 9% of US stocks

Price / book
2.2×

Cheaper than 43% of US stocks

EV / EBITDA
−2.7×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
346.3%

Higher than 97% of US stocks

Earnings growth (YoY)
—
Gross margin
81.6%

Higher than 92% of US stocks

Operating margin
−186.1%

Higher than 11% of US stocks

Net margin
83.6%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−113.1%

Higher than 12% of US stocks

Return on assets
−28.1%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

X4 Pharmaceuticals, Inc. (XFOR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • X4 Pharmaceuticals, Inc. has a market value of $347.0M and an enterprise value of $216.3M.

  • Revenue in the twelve months to 30 June 2026: $15.8M. The latest quarter grew 346.3% year on year.

  • Net income over the same four quarters: −$90.1M, a −568.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$88.7M.

  • Shares outstanding: 96.1M.

  • Trailing P/E: 2.4×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • X4 Pharmaceuticals, Inc. employs 45 people — $352K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

XFOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XFORX4 Pharmaceuticals, Inc.$347.0M
62
IPSCCentury Therapeutics, Inc.$348.5M
39
OCGNOcugen, Inc.$345.3M
22
DMACDiaMedica Therapeutics, Inc.$348.9M
47
EYPTEyePoint, Inc.$350.2M
14
SIONSionna Therapeutics, Inc.$350.3M
26
OBIOOrchestra Biomed Holdings, Inc.$358.1M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own X4 Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XFOR news & analysis

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research · 11 Sept 2026positive

X4 Pharmaceuticals (XFOR) fell 20.8% over four weeks and is now technically in oversold territory, suggesting heavy selling pressure may have been exhausted. The report notes that further agreement among Wall Street analysts in raising earnings estimates could signal a trend reversal for the stock.

Why it matters — XFOR watchers would care because oversold technical conditions combined with upward analyst earnings estimate revisions may indicate the stock's recent decline could be reversing.

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

GlobeNewsWire · 9 Sept 2026neutral

X4 Pharmaceuticals announced that its management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. The company focuses on improving the lives of people with rare hematology diseases.

Why it matters — A scheduled fireside chat at a major healthcare conference gives X4 watchers an opportunity to hear directly from management about the company and its rare hematology disease focus.

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

GlobeNewsWire · 8 Sept 2026positive

X4 Pharmaceuticals announced a positive outcome from its Type C Meeting with the FDA regarding the global 4WARD Phase 3 chronic neutropenia trial. The FDA agreed to a reduced sample size, with enrollment completion expected by year-end 2026 and topline data anticipated in the first half of 2028.

Why it matters — The FDA's agreement to a reduced sample size for the 4WARD Phase 3 trial may streamline the study's path forward for X4 Pharmaceuticals' chronic neutropenia program.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Sept 2026neutral

X4 Pharmaceuticals announced that effective August 31, 2026, the company issued inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards were made pursuant to Nasdaq Listing Rule 5635(c)(4).

Why it matters — X4 watchers would note this as routine equity-based compensation for new hires, a standard administrative move that does not signal a change in business outlook.

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

Zacks Investment Research · 11 Aug 2026positive

X4 Pharmaceuticals (XFOR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.

Why it matters — A XFOR watcher would care because the upgrade signals improving expectations for the company's earnings outlook.

FAQ

Frequently asked questions about XFOR stock

What is the XFOR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XFOR stock a buy right now?

Of the 5 analysts covering X4 Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks X4 Pharmaceuticals, Inc. 62 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XFOR?

As at 12 Sept 2026, X4 Pharmaceuticals, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will XFOR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +242.9% from the last close, and Ticker Nerd's factor model ranks X4 Pharmaceuticals, Inc. 62 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XFOR stock forecast for 2030?

No analyst covering X4 Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XFOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.

How has XFOR stock performed over the past year?

X4 Pharmaceuticals, Inc. returned +6.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does X4 Pharmaceuticals, Inc. do?

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders.

What is the latest news on XFOR?

The most recent item we track (Zacks Investment Research, 11 Sept 2026): "X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner". X4 Pharmaceuticals (XFOR) fell 20.8% over four weeks and is now technically in oversold territory, suggesting heavy selling pressure may have been exhausted. The report notes that further agreement among Wall Street analysts in raising earnings estimates could signal a trend reversal for the stock.

Company

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency. X4 Pharmaceuticals markets XOLREMDI in the United States and continues to evaluate mavorixafor in additional indications through clinical development programs. Its portfolio and commercial activity place it at the intersection of immunology, hematology, and rare-disease care, serving patients with significant unmet medical needs. Based in Boston, Massachusetts, X4 Pharmaceuticals plays a specialized role in the biotechnology market by focusing on treatments for underserved patient populations.

CEO Dr. Paula Ragan Ph.D. · 45 employees · United States · https://www.x4pharma.com